Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $50.8 million.

  • Centessa Pharmaceuticals' Cash & Equivalents fell 8713.73% to $50.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.8 million, marking a year-over-year decrease of 8713.73%. This contributed to the annual value of $383.2 million for FY2024, which is 19932.13% up from last year.
  • Centessa Pharmaceuticals' Cash & Equivalents amounted to $50.8 million in Q3 2025, which was down 8713.73% from $44.2 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Cash & Equivalents high stood at $544.5 million for Q1 2022, and its period low was $44.2 million during Q2 2025.
  • For the 4-year period, Centessa Pharmaceuticals' Cash & Equivalents averaged around $253.1 million, with its median value being $171.5 million (2023).
  • Per our database at Business Quant, Centessa Pharmaceuticals' Cash & Equivalents surged by 19932.13% in 2024 and then plummeted by 8713.73% in 2025.
  • Centessa Pharmaceuticals' Cash & Equivalents (Quarter) stood at $393.6 million in 2022, then tumbled by 67.48% to $128.0 million in 2023, then skyrocketed by 199.32% to $383.2 million in 2024, then plummeted by 86.74% to $50.8 million in 2025.
  • Its last three reported values are $50.8 million in Q3 2025, $44.2 million for Q2 2025, and $105.2 million during Q1 2025.